Lexatumumab

Lexatumumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	TRAIL-R2
Identifiers
CAS Number	845816-02-6
ATC code	none
Chemical data
Formula	C6346H9832N1720O2002S42
Molar mass	143.6 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Lexatumumab (also known as ETR2-ST01) is an agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) used in the treatment of cancer.^[1]

This drug was developed by Human Genome Sciences, Inc.

References

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.

v t e Human monoclonal antibodies ("-u-")
"-limu-" (immune system)	immunosuppression: Adalimumab, Atorolimumab, Fresolimumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab immune activation: Ipilimumab, Tremelimumab other: Bertilimumab, Zanolimumab
"-kinu-" (interleukin as target)	Briakinumab, Canakinumab, Ustekinumab
"-tumu-"/"-tu-" (tumor)	Adecatumumab, Belimumab, Cixutumumab, Conatumumab, Figitumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Necitumumab, Ofatumumab, Olaratumab, Panitumumab, Pritumumab, Robatumumab, Votumumab, Zalutumumab
"-osu-" (bone)	Denosumab
"-mulu-" (musculoskeletal)	Stamulumab^†
"-fungu-" (fungal)	Efungumab
"-viru-" (viral)	Exbivirumab, Foravirumab, Libivirumab, Rafivirumab, Regavirumab, Sevirumab, Tuvirumab
"-bacu-" (bacterial)	Nebacumab, Panobacumab, Raxibacumab
"-ciru-" (cardiovascular)	Ramucirumab
"-neru-" (neurologic)	Gantenerumab
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III